News - Antibiotics and Infectious diseases, Gilead Sciences

Filter

Popular Filters

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

11-02-2014

US biotech major Gilead Sciences has submitted a New Drug Application (NDA) to the US Food and Drug Administration…

Antibiotics and Infectious diseasesBiotechnologyGilead SciencesledipasvirRegulationsofosbuvirUSA

EMA advisory unit issues bunch of positive recommendations

EMA advisory unit issues bunch of positive recommendations

22-11-2013

At its late November meetings, the European Medicines Agency’s Committee for Medicinal Products for…

AB ScienceAnti-viralsAntibiotics and Infectious diseasesAstraZenecaBristol-Myers SquibbDeltybaDiabetesEuropeGilead SciencesLucaneLucane PharmaMasicanOncologyOtsukaPharmaceuticalRegulationSovaldiTivicayViiV HealthcareXigduo

Rise in infections means hepatitis C market is expected to peak at $15.5 billion in 2022

27-08-2013

The hepatitis C market is forecast to increase by a massive 230% in the next nine years, according to…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbGilead SciencesGlobalJohnson & JohnsonMarkets & MarketingPharmaceuticalsofosbuvir

More news from EMA/CHMP September meeting

26-09-2011

Following its meetings last week, the European Medicines Agency’s Committee for Medicinal Products…

Anti-viralsAntibiotics and Infectious diseasesAstellas PharmaCelgeneDificidDificlirEuropeEvipleraGilead SciencesOncologyPharmaceuticalRegulationRevlimidUCBVimpat

Back to top